Data on VIVUS' Qnexa® to be Presented at AADE Annual Meeting

MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in two poster presentations at the 37th Annual American Association of Diabetes Educators (AADE), being held in San Antonio, TX from August 4 - 7, 2010.  Both poster presentations, "Effects of Phentermine/Topiramate on Weight, Glycemic Profiles in Overweight Subjects With Diabetes" and "Glycemic Improvement and Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate," will be held from 6:00-7:30 PM CT on Wednesday, August 4th.

Following are details about the upcoming poster presentations:  

American Association of Diabetes Educators 37th Annual Meeting (AADE) in San Antonio, Texas

Date and Time: Wednesday, August 4, 2010, 6:00-7:30 PM CT

Session: Welcome Poster Reception

Abstract #: 182229

Poster Presentation Title: Effects of Phentermine/Topiramate on Weight, Glycemic Profiles in Overweight Subjects With Diabetes

Authors: Miriam Rueger, RN, MPH, RD, CDE; Timothy Garvey, MD; Le Thu Nguyen, Craig Peterson, MS


Date and Time: Wednesday, August 4, 2010, 6:00-7:30 PM  

Session: Welcome Poster Reception

Abstract #: 181580

Poster Presentation Title: Glycemic Improvement and Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate

Authors: Miriam Rueger, RN, MPH, RD, CDE; Timothy Garvey, MD; Susie Morelos; Barbara Troupin, MD



About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.

CONTACT:






VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris


Brian Korb

Chief Financial Officer


646-378-2923

650-934-5200




Media Relations:

Pure Communications, Inc.



Dan Budwick



973-271-6085



SOURCE VIVUS, Inc.

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.